Table 2.

Comparison of in vitro antibacterial activities of PM181104 and standard antibiotic linezolid^a

Organism (resistance profile)/no. of test strains	MIC (μg/ml)
	PM181104	Linezolid
S. aureus ATCC 3066 (MRSA,b ERYr)	0.032	0.512
S. aureus E710 (MRSA, ERYr)	0.016	2.560
S. aureus ATCC 33591 (MRSAb)	0.032	2.560
E. faecium 02 D3 IP1 (VREd, Teichor)	0.008	2.560
E. faecium R-2 (VREd, vanA)	0.008	2.560
E. faecalis ATCC 29212 (VSEe)	0.016	2.560
E. faecium ATCC 19579	0.032	2.560
E. faecalis ATCC 51299 (VREd, GMr, STRr, vanB)	0.016	2.560
E. faecalis ATCC 47077	0.032	1.280
E. faecalis (LZDr)/5	0.128–0.256	8–32
E. faecalis (GMr)/6c	0.128–0.512	0.5–4
E. faecalis (Dr)/3f	0.256–0.512	1–2

^aMRSA, methicillin resistant Staphylococcus aureus; ERY^r, erythromycin resistant; LZD^r, linezolid resistant; VRE, vancomycin-resistant enterococci; VSE, vancomycin-susceptible enterococci; D^r, doxycycline resistant; GM^r, gentamicin resistant; STR^r, streptomycin resistant; Teicho^r, teichoplanin resistant.

^bMIC of oxacillin, >64 μg/ml.

^cMIC of gentamicin, >32 μg/ml.

^dMIC of vancomycin, >64 μg/ml.

^eMIC of vancomycin range, 0.5–2 μg/ml.

^fMIC of oxacillin range, 16–32 μg/ml.